RESUMEN
We present a rare case of primary tracheal schwannoma in a 49-year-old man who had experienced obstructive airway symptoms for 4 years. Computed Tomography (CT) showed an intratracheal polipoid mass lesion originating from the left lateral wall. Fibre-optic bronchoscopy revealed the diagnosis of an intratracheal poylpoid mass obstructing 70% of the lumen. After diagnosing a benign lesion by punch biopsies with bronchoscopy, thoracotomy was performed and the tumour was totally excised. Histopathological examination revealed a benign neurogenic tumour of schwann cell origin.
Asunto(s)
Neurilemoma , Neoplasias de la Tráquea , Obstrucción de las Vías Aéreas/etiología , Broncoscopía , Humanos , Masculino , Persona de Mediana Edad , Neurilemoma/complicaciones , Neurilemoma/patología , Neurilemoma/cirugía , Tomografía Computarizada Espiral , Neoplasias de la Tráquea/complicaciones , Neoplasias de la Tráquea/patología , Neoplasias de la Tráquea/cirugíaRESUMEN
The objective of this study was to determine the effects of a once-monthly injectable contraceptive (Mesigyna) on menstrual pattern, lipoproteins, and coagulation parameters. Thirty-six women aged 18-35 years requesting monthly injectable contraception were included. Before injecting estradiol valerate 5 mg and norethisterone enanthate 50 mg, coagulation, lipoprotein, and liver function parameters were determined. After the 3- and 6-month injections, the same coagulation and serum lipid measurements and liver function tests were repeated, and women were questioned about their menstrual patterns and side effects. Thirty women who completed 6 months were evaluated. At the end of 3 months, two-thirds of the 30 women had normal menstrual patterns; at the end of 6 months, 80% of the women had normal menses. Serum LDL, total cholesterol, and triglyceride levels did not change significantly, while HDL and VLDL decreased significantly (p = 0.032 and p = 0.039, respectively) at 6 months. PT and aPTT measures did not change at the end of 6 months, while fibrinogen levels were significantly lower (p = 0.013). Serum total bilirubin levels increased (p = 0.022) and albumin levels decreased (p = 0.022) at the end of 6 months. Mesigyna was well tolerated and side effects and menstrual abnormalities were acceptable. There were no clinically significant changes in lipoprotein, coagulation, or hepatic parameters.